Results 31 to 40 of about 359,805 (237)
Chlorella vulgaris biorefineries: sustainable biofuels and high‐value carbon capture
Biofuels, Bioproducts and Biorefining, EarlyView.Abstract Global reliance on fossil fuels has created urgent economic and environmental challenges, yet large‐scale use of algal biomass remains limited by production costs. Industrial scaling is constrained by inefficient harvesting and the technical challenges of processing recalcitrant cell walls.
Sandyelle Ferreira Alcântara Araújo +13 more
wiley +1 more source
The European Council [Copenhagen Summit 1993], Copenhagen, 21-22 June 1993 [PDF]
, 1993 Dossier ...
core
‘Relais actors’ and co-decision first reading agreements in the European Parliament : the case of the advanced therapies regulation [PDF]
, 2011 The processing of the advanced therapies regulation is of particular interest to scholars of the European Union's (EU) legislative process and students of the European Parliament (EP) because it provides a case study which throws light upon assumptions ...
Earnshaw, D., Judge, D.
core +1 more source
Prescribing competence: The pros and cons of different methods for assessment
British Journal of Clinical Pharmacology, EarlyView.Evaluating a medical graduate’s competence in rational prescribing is challenging. With the aim to guide and inspire teachers, this narrative review explores different methods that can be used to assess prescribing competence. Each method has its own advantages and disadvantages, and thus a mix of different assessment methods is needed throughout the ...
David J. Brinkman +3 more
wiley +1 more source
The European Council [Copenhagen Summit 1978], Copenhagen, 7-8 April 1978 [PDF]
, 1978 Dossier: Conclusions, statement by European Parliament President Emilio Colombo, statement by European Commission President Roy Jenkins, article on Community-Japanese ...
core
British Journal of Clinical Pharmacology, EarlyView.Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló +5 more
wiley +1 more source
How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU
British Journal of Clinical Pharmacology, EarlyView.The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley +1 more source
Take away/take the word: censorship, prohibition and secrecy in literature and publishing
Estudios de Teoría Literaria, 2022 Readers of this dossier will find here an invitation to analyze some of the effects of what John M. Coetzee called the "passion to silence" (Coetzee), an issue that, we maintain, is more relevant today than ever in the face of the worrying rise of new ...
Laura Maccioni, Amandine Guillard
doaj
British Journal of Clinical Pharmacology, EarlyView.Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden +3 more
wiley +1 more source